1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 4
FEATURED COMPANIES
- Genea Ltd.
- Igenomix Sl
- Illumina Inc.
- Invitae Corp.
- Natera Inc.
- PerkinElmer Inc.
- MORE
Global Preimplantation Genetic Diagnosis (PGD) Market: About this market
Preimplantation genetic diagnosis (PGD) is a genetic testing procedure that is performed before the implantation of oocytes or embryos for the identification of genetic abnormalities, such as aneuploidy, single-gene disorders, and X- and Y-linked disorders. It is commonly performed when one or both expecting parents have such abnormalities and are at a high risk of passing them to their offspring. The preimplantation genetic diagnosis market analysis considers sales of devices to fertility clinics and maternity centers, hospitals and diagnostic laboratories, and research institutions. Our analysis also considers the sales of preimplantation genetic diagnosis in Asia, Europe, North America, and ROW. In 2018, the fertility clinics and maternity centers segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as the rising demand for PGD testing to increase the chances of successful IVF pregnancies in couples with previous unexplainable IVF failures will significantly help the segment in maintaining its leading market position. Also, our global preimplantation genetic diagnosis report has observed market growth factors such as increasing demand for early diagnosis of genetic disorders, rising adoption of IVF treatments, and decreasing cost of genetic sequencing and IVF treatments. However, challenges such as the presence of stringent regulations related to genetic diagnosis, ethical concerns associated with genetic testing of embryos, and concerns about safety and privacy of genetic data may hamper the growth of the preimplantation genetic diagnosis industry over the forecast period.
Global Preimplantation Genetic Diagnosis Market: Overview
Increasing demand for early diagnosis of genetic disorders
With advances in the diagnostic and treatment procedures in the healthcare sector, the demand for early diagnostic techniques is rising. The need for early diagnosis, during genetic IVF techniques and other artificial insemination procedures, has become crucial owing to the rising need to prevent health conditions in new-borns. Furthermore, governments and non-profit organizations are organizing awareness programs about the benefits of early diagnosis of genetic disorders to promote the wellbeing of women and children. Vendors are capitalizing on these factors and are increasingly offering PGD devices. As a result, the global preimplantation genetic diagnosis market will record a CAGR of over 10% during 2019-2023.
Growing demand for non-invasive biopsy procedures in PGD
Vendors are focusing on further innovation on PGD procedures to increase their sales volume an cater to the rising demand for improved techniques. This gave rise to non-invasive biopsy procedures, which offer several benefits over conventional biopsy procedures and avoid risks associated with the removal of cells from embryos. Therefore, the demand for non-invasive biopsy procedures in PGD is growing, which is one of the key preimplantation genetic diagnosis market trends. The trend is expected to have a positive impact on the overall preimplantation genetic diagnosis market growth during the forecast period.
Competitive Landscape
With the presence of a few major players, the global preimplantation genetic diagnosis market is moderately concentrated. The robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of few leading vendors such as Genea Ltd., Igenomix Sl, Illumina Inc., Invitae Corp., Laboratory Corp. of America Holdings, Natera Inc., Oxford Gene Technology Group, PerkinElmer Inc., Quest Diagnostics Inc., and Thermo Fisher Scientific Inc.
Also, the preimplantation genetic diagnosis market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies in strategizing and leveraging on all forthcoming growth opportunities.
Preimplantation genetic diagnosis (PGD) is a genetic testing procedure that is performed before the implantation of oocytes or embryos for the identification of genetic abnormalities, such as aneuploidy, single-gene disorders, and X- and Y-linked disorders. It is commonly performed when one or both expecting parents have such abnormalities and are at a high risk of passing them to their offspring. The preimplantation genetic diagnosis market analysis considers sales of devices to fertility clinics and maternity centers, hospitals and diagnostic laboratories, and research institutions. Our analysis also considers the sales of preimplantation genetic diagnosis in Asia, Europe, North America, and ROW. In 2018, the fertility clinics and maternity centers segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as the rising demand for PGD testing to increase the chances of successful IVF pregnancies in couples with previous unexplainable IVF failures will significantly help the segment in maintaining its leading market position. Also, our global preimplantation genetic diagnosis report has observed market growth factors such as increasing demand for early diagnosis of genetic disorders, rising adoption of IVF treatments, and decreasing cost of genetic sequencing and IVF treatments. However, challenges such as the presence of stringent regulations related to genetic diagnosis, ethical concerns associated with genetic testing of embryos, and concerns about safety and privacy of genetic data may hamper the growth of the preimplantation genetic diagnosis industry over the forecast period.
Global Preimplantation Genetic Diagnosis Market: Overview
Increasing demand for early diagnosis of genetic disorders
With advances in the diagnostic and treatment procedures in the healthcare sector, the demand for early diagnostic techniques is rising. The need for early diagnosis, during genetic IVF techniques and other artificial insemination procedures, has become crucial owing to the rising need to prevent health conditions in new-borns. Furthermore, governments and non-profit organizations are organizing awareness programs about the benefits of early diagnosis of genetic disorders to promote the wellbeing of women and children. Vendors are capitalizing on these factors and are increasingly offering PGD devices. As a result, the global preimplantation genetic diagnosis market will record a CAGR of over 10% during 2019-2023.
Growing demand for non-invasive biopsy procedures in PGD
Vendors are focusing on further innovation on PGD procedures to increase their sales volume an cater to the rising demand for improved techniques. This gave rise to non-invasive biopsy procedures, which offer several benefits over conventional biopsy procedures and avoid risks associated with the removal of cells from embryos. Therefore, the demand for non-invasive biopsy procedures in PGD is growing, which is one of the key preimplantation genetic diagnosis market trends. The trend is expected to have a positive impact on the overall preimplantation genetic diagnosis market growth during the forecast period.
Competitive Landscape
With the presence of a few major players, the global preimplantation genetic diagnosis market is moderately concentrated. The robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of few leading vendors such as Genea Ltd., Igenomix Sl, Illumina Inc., Invitae Corp., Laboratory Corp. of America Holdings, Natera Inc., Oxford Gene Technology Group, PerkinElmer Inc., Quest Diagnostics Inc., and Thermo Fisher Scientific Inc.
Also, the preimplantation genetic diagnosis market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies in strategizing and leveraging on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- Genea Ltd.
- Igenomix Sl
- Illumina Inc.
- Invitae Corp.
- Natera Inc.
- PerkinElmer Inc.
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
Exhibit 01: Product overview
Exhibit 02: Global healthcare market
Exhibit 03: Segments of global healthcare market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: End-user - Market share 2018-2023 (%)
Exhibit 19: Comparison by end-user
Exhibit 20: Fertility clinics and maternity centers - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Fertility clinics and maternity centers - Year-over-year growth 2019-2023 (%)
Exhibit 22: Hospitals and diagnostic laboratories - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Hospitals and diagnostic laboratories - Year-over-year growth 2019-2023 (%)
Exhibit 24: Research institutes - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Research institutes - Year-over-year growth 2019-2023 (%)
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Genea Ltd. - Vendor overview
Exhibit 46: Genea Ltd. - Business segments
Exhibit 47: Genea Ltd. - Organizational developments
Exhibit 48: Genea Ltd. - Key offerings
Exhibit 49: Igenomix Sl - Vendor overview
Exhibit 50: Igenomix Sl - Business segments
Exhibit 51: Igenomix Sl - Organizational developments
Exhibit 52: Igenomix Sl - Key offerings
Exhibit 53: Illumina Inc. - Vendor overview
Exhibit 54: Illumina Inc. - Business segments
Exhibit 55: Illumina Inc. - Organizational developments
Exhibit 56: Illumina Inc. - Geographic focus
Exhibit 57: Illumina Inc. - Segment focus
Exhibit 58: Illumina Inc. - Key offerings
Exhibit 59: Invitae Corp. - Vendor overview
Exhibit 60: Invitae Corp. - Business segments
Exhibit 61: Invitae Corp. - Organizational developments
Exhibit 62: Invitae Corp. - Geographic focus
Exhibit 63: Invitae Corp. - Key offerings
Exhibit 64: Laboratory Corp. of America Holdings - Vendor overview
Exhibit 65: Laboratory Corp. of America Holdings - Business segments
Exhibit 66: Laboratory Corp. of America Holdings - Organizational developments
Exhibit 67: Laboratory Corp. of America Holdings - Geographic focus
Exhibit 68: Laboratory Corp. of America Holdings - Segment focus
Exhibit 69: Laboratory Corp. of America Holdings - Key offerings
Exhibit 70: Natera Inc. - Vendor overview
Exhibit 71: Natera Inc. - Business segments
Exhibit 72: Natera Inc. - Organizational developments
Exhibit 73: Natera Inc. - Geographic focus
Exhibit 74: Natera Inc. - Key offerings
Exhibit 75: Oxford Gene Technology Group - Vendor overview
Exhibit 76: Oxford Gene Technology Group - Business segments
Exhibit 77: Oxford Gene Technology Group - Organizational developments
Exhibit 78: Oxford Gene Technology Group - Key offerings
Exhibit 79: PerkinElmer Inc. - Vendor overview
Exhibit 80: PerkinElmer Inc. - Business segments
Exhibit 81: PerkinElmer Inc. - Organizational developments
Exhibit 82: PerkinElmer Inc. - Geographic focus
Exhibit 83: PerkinElmer Inc. - Segment focus
Exhibit 84: PerkinElmer Inc. - Key offerings
Exhibit 85: Quest Diagnostics Inc. - Vendor overview
Exhibit 86: Quest Diagnostics Inc. - Business segments
Exhibit 87: Quest Diagnostics Inc. - Organizational developments
Exhibit 88: Quest Diagnostics Inc. - Segment focus
Exhibit 89: Quest Diagnostics Inc. - Key offerings
Exhibit 90: Thermo Fisher Scientific Inc. - Vendor overview
Exhibit 91: Thermo Fisher Scientific Inc. - Business segments
Exhibit 92: Thermo Fisher Scientific Inc. - Organizational developments
Exhibit 93: Thermo Fisher Scientific Inc. - Geographic focus
Exhibit 94: Thermo Fisher Scientific Inc. - Segment focus
Exhibit 95: Thermo Fisher Scientific Inc. - Key offerings
Exhibit 96: Validation techniques employed for market sizing
Exhibit 97: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by end-user
- Comparison by end-user
- Fertility clinics and maternity centers - Market size and forecast 2018-2023
- Hospitals and diagnostic laboratories - Market size and forecast 2018-2023
- Research institutes - Market size and forecast 2018-2023
- Market opportunity by end-user
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Advances in genetic sequencing technologies
- Rising adoption of online testing kits and services
- Growing demand for non-invasive biopsy procedures in PGD
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Genea Ltd.
- Igenomix Sl
- Illumina Inc.
- Invitae Corp.
- Laboratory Corp. of America Holdings
- Natera Inc.
- Oxford Gene Technology Group
- PerkinElmer Inc.
- Quest Diagnostics Inc.
- Thermo Fisher Scientific Inc.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Product overview
Exhibit 02: Global healthcare market
Exhibit 03: Segments of global healthcare market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: End-user - Market share 2018-2023 (%)
Exhibit 19: Comparison by end-user
Exhibit 20: Fertility clinics and maternity centers - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Fertility clinics and maternity centers - Year-over-year growth 2019-2023 (%)
Exhibit 22: Hospitals and diagnostic laboratories - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Hospitals and diagnostic laboratories - Year-over-year growth 2019-2023 (%)
Exhibit 24: Research institutes - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Research institutes - Year-over-year growth 2019-2023 (%)
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Genea Ltd. - Vendor overview
Exhibit 46: Genea Ltd. - Business segments
Exhibit 47: Genea Ltd. - Organizational developments
Exhibit 48: Genea Ltd. - Key offerings
Exhibit 49: Igenomix Sl - Vendor overview
Exhibit 50: Igenomix Sl - Business segments
Exhibit 51: Igenomix Sl - Organizational developments
Exhibit 52: Igenomix Sl - Key offerings
Exhibit 53: Illumina Inc. - Vendor overview
Exhibit 54: Illumina Inc. - Business segments
Exhibit 55: Illumina Inc. - Organizational developments
Exhibit 56: Illumina Inc. - Geographic focus
Exhibit 57: Illumina Inc. - Segment focus
Exhibit 58: Illumina Inc. - Key offerings
Exhibit 59: Invitae Corp. - Vendor overview
Exhibit 60: Invitae Corp. - Business segments
Exhibit 61: Invitae Corp. - Organizational developments
Exhibit 62: Invitae Corp. - Geographic focus
Exhibit 63: Invitae Corp. - Key offerings
Exhibit 64: Laboratory Corp. of America Holdings - Vendor overview
Exhibit 65: Laboratory Corp. of America Holdings - Business segments
Exhibit 66: Laboratory Corp. of America Holdings - Organizational developments
Exhibit 67: Laboratory Corp. of America Holdings - Geographic focus
Exhibit 68: Laboratory Corp. of America Holdings - Segment focus
Exhibit 69: Laboratory Corp. of America Holdings - Key offerings
Exhibit 70: Natera Inc. - Vendor overview
Exhibit 71: Natera Inc. - Business segments
Exhibit 72: Natera Inc. - Organizational developments
Exhibit 73: Natera Inc. - Geographic focus
Exhibit 74: Natera Inc. - Key offerings
Exhibit 75: Oxford Gene Technology Group - Vendor overview
Exhibit 76: Oxford Gene Technology Group - Business segments
Exhibit 77: Oxford Gene Technology Group - Organizational developments
Exhibit 78: Oxford Gene Technology Group - Key offerings
Exhibit 79: PerkinElmer Inc. - Vendor overview
Exhibit 80: PerkinElmer Inc. - Business segments
Exhibit 81: PerkinElmer Inc. - Organizational developments
Exhibit 82: PerkinElmer Inc. - Geographic focus
Exhibit 83: PerkinElmer Inc. - Segment focus
Exhibit 84: PerkinElmer Inc. - Key offerings
Exhibit 85: Quest Diagnostics Inc. - Vendor overview
Exhibit 86: Quest Diagnostics Inc. - Business segments
Exhibit 87: Quest Diagnostics Inc. - Organizational developments
Exhibit 88: Quest Diagnostics Inc. - Segment focus
Exhibit 89: Quest Diagnostics Inc. - Key offerings
Exhibit 90: Thermo Fisher Scientific Inc. - Vendor overview
Exhibit 91: Thermo Fisher Scientific Inc. - Business segments
Exhibit 92: Thermo Fisher Scientific Inc. - Organizational developments
Exhibit 93: Thermo Fisher Scientific Inc. - Geographic focus
Exhibit 94: Thermo Fisher Scientific Inc. - Segment focus
Exhibit 95: Thermo Fisher Scientific Inc. - Key offerings
Exhibit 96: Validation techniques employed for market sizing
Exhibit 97: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
FEATURED COMPANIES
- Genea Ltd.
- Igenomix Sl
- Illumina Inc.
- Invitae Corp.
- Natera Inc.
- PerkinElmer Inc.
- MORE
The following companies are recognised as the key players in the global preimplantation genetic diagnosis market: Genea Ltd., Igenomix Sl, Illumina Inc., Invitae Corp., Laboratory Corp. of America Holdings, Natera Inc., Oxford Gene Technology Group, PerkinElmer Inc., Quest Diagnostics Inc., and Thermo Fisher Scientific Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the growing demand for non-invasive biopsy procedures in PGD.”
According to the report, one of the major drivers for this market is the increasing demand for early diagnosis of genetic disorders.
Further, the report states that one of the major factors hindering the growth of this market is the presence of stringent regulations related to genetic diagnosis.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the growing demand for non-invasive biopsy procedures in PGD.”
According to the report, one of the major drivers for this market is the increasing demand for early diagnosis of genetic disorders.
Further, the report states that one of the major factors hindering the growth of this market is the presence of stringent regulations related to genetic diagnosis.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
- Genea Ltd.
- Igenomix Sl
- Illumina Inc.
- Invitae Corp.
- Laboratory Corp. of America Holdings
- Natera Inc.
- Oxford Gene Technology Group
- PerkinElmer Inc.
- Quest Diagnostics Inc.
- Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown
